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Abstract We recently demonstrated that two exclusively Gi- 
coupled isoforms of the mouse EP3 receptor, EP3a and 13, with 
different carboxyl-terminal tails, differed in agonist-independent 
constitutive Gi activity, and the carboxyl-terminal tail-truncated 
receptor showed full constitutive activity (Hasegawa, H., 
Negishi, M., and Ichikawa, A. (1996) J. Biol. Chem. 271, 
1857-1860). Here we further examined Gi and Gs activities of 
the third isoform, EP3T, coupled to both Gi and Gs. The EP3 T 
receptor showed mostly full constitutive Gi activity and agonist- 
dependent Gs activity. The truncated receptor also showed 
agonist-dependent Gs activity, but the level was lower than that 
of the EP3T receptor. Thus, the carboxyl-terminal tail would 
differentially regulate Gi and Gs activities of the EP3 receptor. 
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1. Introduction 
EP3 receptor in coupling to G proteins, we constructed a 
mutated EP3 receptor, T-335, in which the COOH-terminal 
tail was truncated at the alternative splicing site, and revealed 
that the truncated receptor showed only agonist-independent 
constitutive Gi activity, suggesting that the COOH-terminal 
tails after the alternative splicing site suppress activation of Gi 
by the EP3 receptor [13]. In addition to EP3c~ and [3, which 
are exclusively coupled to Gi, we further identified a third 
isoform, EP37, which was also produced through alternative 
splicing and differed in the COOH-terminal tail from the 
other two isoforms [14]. However, the EP37 receptor was 
coupled to both Gi and Gs, suggesting that the COOH-ter- 
minal tails of the EP3 receptor play an important role in the 
specificity of G protein coupling. To assess the role of the 
COOH-terminal tail of the EP3y receptor in G protein cou- 
pling, we studied in more detail Gi and Gs activities of the 
EP3y and truncated receptors. We report here that the EP3"f 
receptor showed mostly full constitutive Gi activity and the 
truncated receptor had agonist-dependent Gs activity. 
Prostaglandin E2 (PGE2) produces a broad range of biolog- 
ical actions in diverse tissues through its binding to specific 
receptors on plasma membranes [1]. PGE receptors are phar- 
macologically subdivided into four subtypes, EP1, EP2, EP3, 
and EP4, on the basis of their responses to various agonists 
and antagonists [2,3]. Among these subtypes, the EP3 receptor 
has been best characterized; it has been suggested to be in- 
volved in such PGE2 actions as contraction of the uterus [4], 
inhibition of gastric acid secretion [5], modulation of the neu- 
rotransmitter release [6], lipolysis in adipose tissue [7], and 
sodium and water reabsorption i the kidney tubules [8]. Vari- 
ous EP3 receptor-mediated actions are mediated through mul- 
tiple signal transduction systems, and in addition, the dose- 
response curve and potency of PGE2 vary with tissue, imply- 
ing heterogeneity of EP3 receptors [9,10]. 
We have cloned the mouse EP3 receptor and demonstrated 
that this receptor is a G protein-coupled rhodopsin-type r - 
ceptor that engages in inhibition of adenylate cyclase [11]. 
Furthermore, we identified two isoforms of the mouse EP3 
receptor, EP3c~ and EP313, with a different COOH-terminal 
tail, which were produced through alternative splicing and 
differed in agonist-independent constitutive Gi activity; the 
EP3c~ receptor showed marked agonist-independent Gi activ- 
ity, while the EP313 receptor had no constitutive activity 
[12,13]. To assess the role of the COOH-terminal tails of the 
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2. Materials and methods 
2.1. Materials 
Sulprostone and TEI-3356 were generous gifts from Dr. K.-H. 
Thierauch of Schering and Dr. S. Kurozumi of Teijin Ltd., respec- 
tively. The 12SI-labeled cAMP assay system was obtained from Amer- 
sham Corp; pertussis toxin (PT) was from Seikagaku Kogyo (Tokyo, 
Japan); forskolin was from Sigma. 
Chinese hamster ovary (CHO) cells stably expressing the EP3o~, 
EP313 [12], EP3y [14], or the truncated receptor, T-335 [15], were 
cultured in the a-modification ofEagle's medium lacking ribonucleo- 
sides and deoxyribonucleosides, with10% dialyzed fetal bovine serum 
under humidified air containing 5% CO2 at 37°C. 
2.2. Measurement of cAMP formation 
Cyclic AMP levels in CHO cells were determined asreported pre- 
viously [16]. The receptor-expressing CHO cells cultured in 24-well 
plates (5× 105 cells/well) were washed with HEPES-buffered saline 
containing 140 mM NaCI, 4.7 mM KC1, 2.2 mM CaC12, 1.2 mM 
MgCI2, 1.2 mM KH2PO4, 11 mM glucose, and 15 mM HEPES, pH 
7.4, and preincubated for 5 min. Reactions were started by the addi- 
tion of test agents along with 100 gM Ro-20-1724. After incubation 
for 10 min at 37°C, reactions were terminated by the addition of 10% 
trichloroacetic a id. The content of cAMP in the cells was measured 
by radioimmunoassay with an Amersham cAMP assay system. 
3. Results and discussion 
The EP3~t receptor is coupled to both Gi and Gs. We have 
recently demonstrated that the interaction of the carboxylic 
acid of PGE2 and arginine residue of the seventh transmem- 
brane domain of EP3 receptor was not essential for Gi cou- 
pling but was necessary for Gs coupling, and sulprostone, an 
EP3 agonist having the methanesulfonamide-modified car- 
boxylic acid, induced preferential coupling of the EP3 recep- 
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tor to Gi [17]. To determine the Gi activity of the EP3y re- 
ceptor, we used sulprostone as an agonist. We tested the abil- 
ity of the EP3y receptor to inhibit the forskolin-activated a e- 
nylate cyclase in the presence or absence of sulprostone, and 
compared the ability with those of the EP3c¢, EP31], and the 
truncated receptor, T-335 (Fig. 1). In the absence of the ago- 
nist, forskolin increased the intracellular cAMP levels in the 
order of EP31]>EP3tx>EP3y>T-335. The EP3y receptor 
showed the lowest level among the three isoforms, the level 
being close to that in the T-335 receptor. Sulprostone concen- 
tration-dependently inhibited the forskolin-stimulated cAMP 
formation in the three EP3 receptor isoforms. The IC50 value 
for the inhibition and the maximally reduced cAMP level 
decreased in the order of the EP3y (0.03 nM)>EP3tx (0.1 
nM)>EP31] (30 nM). The EP3y receptor had the lowest IC~0 
value and the lowest cAMP level among the three isoforms. 
To assess the constitutive activity of the EP3y receptor, we 
examined the effect of PT on the Gi activity of the receptor. 
As shown in Fig. 2A, PT treatment concentration-dependently 
increased the forskolin-stimulated cAMP formation in the ab- 
sence of the agonist and maximally elevated at the level about 
4-fold over the level without reatment at 100 ng/ml. PT treat- 
ment attenuated the sulprostone-induced inhibition of the for- 
skolin-stimulated cAMP formation, the cAMP level reaching 
the same value as that in the absence of the agonist. This 
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Fig. 1. Inhibition of adenylate cyclase by the three EP3 receptor iso- 
forms and T-335 receptor. CHO cells expressing EP3ct ([5), EP3~3 
(a), EP3y (e), or T-335 receptor (O) were incubated at 37°C for 
10 min with 10 ~tM forskolin in the presence or absence of the indi- 
cated concentrations of sulprostone, then cAMP contents were 
determined as described in section 2. The results hown are the 
means + S.E.M. for triplicate determinations. 
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Fig. 2. Effects of PT treatment on agonist-dependent or -indepen- 
dent inhibition of adenylate cyclase by the EP3 receptor isoforms 
and T-335 receptor. A: After cells expressing the EP3y receptor had 
been treated with the indicated concentrations of PT for 5 h, they 
were incubated at 37°C for 10 min with 10 ktM forskolin in the ab- 
sence (e) or presence ((3) of 0.1 I.tM sulprostone, then cAMP con- 
tents were determined as described in Section 2. B: After cells ex- 
pressing EP3ct, EP3~, EP3y, or T-335 receptor had been treated 
with (dotted bars, hatched bars) or without (open bars, black bars) 
10 ng/ml PT for 5 h, they were incubated at 37°C for 10 min with 
10 laM forskolin in the absence (open bars, dotted bars) or presence 
(black bars, hatched bars) of 0.1 IxM sulprostone, then cAMP con- 
tents were determined as described in section 2. The results hown 
are the means + S.E.M. for triplicate determinations. 
indicates that most of the EP3y receptor is constitutively ac- 
tive receptor. We further compared the effect of PT on the 
agonist-dependent or independent Gi activity of the EP37 re- 
ceptor and the other receptors. As shown in Fig. 2B, PT 
treatment increased the forskolin-stimulated cAMP formation 
in the absence of the agonist in the EP3ct, EP37 and T-335 
receptors to similar levels, and attenuated the sulprostone- 
induced inhibition in the EP3c¢ and EP37 receptors. On the 
other hand, no PT treatment-induced increase in forskolin- 
stimulated cAMP formation in the absence of the agonist 
was observed with the EP31] receptor, and this treatment 
rather suppressed the level, as reported previously [13]. This 
suppression by PT was also observed in the mock-transfected 
cells, indicating that the suppression is not due to the effect on 
the receptor function [13]. Thus, the constitutive Gi activity 
increased in the order of T-335>EP3y>EP3ct>EP313, andthe 
EP3y receptor showed the highest constitutive Gi activity 
among the three isoforms. 
Lefkowitz and co-workers have proposed a two-state model 
in which receptors are in equilibrium between the inactive 
conformation and the active conformation that can associate 
and activate G protein [18]. Receptors mostly have the inac- 
tive conformation i the absence of ligands and prevent heir 
G protein activation domains from association with G pro- 
teins. Classical agonists release the constraint and increase the 
concentration f the active conformation of the receptors [18]. 
In this regard, the EP37 receptor is a novel receptor, displac- 
ing the equilibrium towards the active conformation i  the 
absence of ligands. The EP3y receptor is the first example of 
native receptor with mostly full constitutive activity. We pre- 
viously showed that the EP37 receptor was expressed in a 
variety of tissues [14]. The expression of the receptor would 
induce sustained inhibition of adenylate cyclase, and the ex- 
pression level would regulate the cAMP response. The three 
EP3 receptor isoforms differ only in the COOH-terminal tail, 
showing different constitutive activity, and the truncated re- 
ceptor exhibits full agonist-independent constitutive activity. 
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Fig. 3. Stimulation of adenylate cyclase by the three EP3 receptor 
isoforms and T-335 receptor. After cells expressing EP3ot ([]), EP313 
(a), EP37 (O), or T-335 receptor (0) had been treated with (B) or 
without (A) 10 ng/ml PT for 5 h, they were incubated at 37°C for 
10 min with the indicated concentrations of TEI-3356, then cAMP 
contents were determined as described in section 2. The results 
shown are the means + S.E.M. for triplicate determinations. 
This suggests that the COOH-terminal tails after the alterna- 
tive splicing site suppress activation of Gi by the EP3 receptor 
to different extents dependent on the structure of the COOH- 
terminal tail, and the suppression by the tail of the EP3T 
receptor may be very low. In addition to constitutive Gi ac- 
tivity, the three isoforms differed in ICs0 value for the agonist- 
mediated inhibition and the maximal inhibition response (Fig. 
1). According to the two-state model of receptor activation, 
the two parameters, ICs0 and maximal response, are depen- 
dent on the level of constitutive activity of receptor. As the 
percentage of constitutive activity increases, the value of ICs0 
decreases and the level of maximal response increases [19]. 
Variation of the two parameters of three EP3 receptor iso- 
forms are consistent with the diversity of constitutive Gi ac- 
tivities of the receptors. The EP3 receptor isoforms with dif- 
ferent constitutive activity produce diverse agonist sensitivity. 
The human EP3 receptor has been reported to have several 
isoforms, which were also produced through alternative splic- 
ing and differed only in the COOH-terminal tail, and they 
showed Gi activity but the levels of forskolin-stimulated 
cAMP formation in the absence of agonist varied among 
the isoforms [20]. These findings suggest hat EP3 receptor 
isoforms differ in constitutive Gi activity, and the structures 
of the COOH-terminal tail add the receptor variation of con- 
stitutive Gi activity. 
To assess the role of the COOH-terminal tails in the cou- 
pling of the EP3 receptor to Gs, we next examined the Gs 
activities of the three EP3 receptor isoforms and T-335 recep- 
tor. CHO cells slightly expressed the PGE receptor EP4 sub- 
type, which is coupled to Gs, and the cells produced a sig- 
nificant amount of cAMP in response to PGE2 or agonists 
cross-reactive to the EP4 subtype (data not shown). We re- 
cently found that TEI-3356 was a highly selective agonist for 
subtype EP3, and this agonist did not increase the cAMP level 
of mock-transfected CHO cells by 100 gM [21]. Thus, we 
chose TEI-3356 as an agonist for determination f EP3 recep- 
tor-mediated stimulation of cAMP formation. In cells not 
treated with PT, TEI-3356 did not affect the basal cAMP level 
in the EP3a-, EP31$-, or T-335-expressing cells, but the agonist 
concentration-dependently i creased the cAMP level in the 
EP3y-expressing cells (Fig. 3A). To ablate receptor coupling 
to Gi, the cells were treated with PT, and we examined the Gs 
activities of the receptors. As shown in Fig. 3B, TEI-3356 
concentration-dependently increased the cAMP level in the 
cells expressing the three isoforms and the truncated receptor, 
the maximal levels increasing in the order of EP3y> 
T-335>EP3cx>EP313. The cAMP levels in the absence of the 
agonist in the cells expressing the receptors were the same as 
that in the mock-transfected cells (0.204 pmol/10 ~cells), in- 
dicating that the three isoforms and T-335 receptor have no 
constitutive Gs activity. The EP3y receptor showed marked 
Gs activity in the cells not treated with PT, even though the 
receptor had the agonist-independent constitutive Gi activity. 
On the other hand, the Gs activities of the EP3c~ and T-335 
receptors were observed only in the condition of ablation of 
Gi coupling. The T-335 receptor has agonist-dependent Gs 
activity without he constitutive activity. Therefore, Gs activa- 
tion is an intrinsic ability of the EP3 receptor, but the COOH- 
terminal tail is not the domain for Gs activation. On the other 
hand, the Gs activity of the EP3y receptor was higher than 
that of the truncated receptor, T-335, while the activities of 
the EP3c~ and EP3I] receptor were lower than that of the 
T-335 receptor. The COOH-terminal tail of the EP3y receptor 
may enhance the Gs activity of the EP3 receptor, but the tails 
of the EP3cc and EP313 receptors uppress the activity, suggest- 
ing that the COOH-terminal tails modulate the Gs activity of 
the EP3 receptor. 
In summary, we present evidence here that the EP3y recep- 
tor isoform shows mostly full constitutive Gi activity, suggest- 
ing that the COOH-terminal tail of the EP3y receptor has low 
potency in the constraint of the EP3 receptor in its inactive 
conformation. We also show that the truncated receptor has 
agonist-dependent Gs activity and the COOH-terminal tails of 
the EP3 receptor modulate this activity. This study will con- 
tribute not only to an understanding of the heterogeneity of 
PGE2 actions but will also help to elucidate the molecular 
mechanism of G protein activation induced by receptors. 
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